Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cellectis SA ( (CLLS) ) has issued an announcement.
On March 31, 2025, Cellectis S.A. announced an update to its UCART pipeline, highlighting the progress of its and its licensees’ most advanced product candidates in clinical development. The update provides detailed information about the Phase 2 trials for ALLO-501A and IOV-4001, indicating the company’s ongoing commitment to advancing its clinical programs and potentially strengthening its position in the biotechnology industry.
More about Cellectis SA
Cellectis S.A. is a biotechnology company based in Paris, France, specializing in the development of gene-edited cell therapies. The company focuses on creating innovative solutions for cancer treatment through its proprietary gene-editing technologies.
YTD Price Performance: -29.83%
Average Trading Volume: 398,481
Technical Sentiment Signal: Buy
Current Market Cap: $94.81M
For a thorough assessment of CLLS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges